Latest news with #EvolentHealth
Yahoo
2 days ago
- Business
- Yahoo
Evolent To Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025
Company to Participate in Upcoming Conferences WASHINGTON, July 14, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its second quarter 2025 financial results on Thursday, August 7, 2025, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, Analysts interested in asking questions during the live call should dial 855.940.9467, or 412.317.6034 for international callers, and reference the "Evolent call" 15 minutes prior to the call. An audio playback of the conference call will be available on Evolent's investor relations website for 90 days after the call. Upcoming Investor Events Additionally, Evolent announced that its executive management team will participate in upcoming investor conferences.A live audio-only webcast and replay for these events will be available on the "Events and Presentations" section of Evolent's investor relations website. Presentation webcast times will be posted on the website as they become available. Canaccord Genuity 44th Annual Growth Conference at the Intercontinental Boston in Boston, Massachusetts on August 13, 2025 About Evolent Evolent (NYSE: EVH) specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable. Evolent serves a national base of leading payers and providers and is consistently recognized as a top place to work in health care nationally. Learn more about how Evolent is changing the way health care is delivered by visiting Contacts:investorrelations@ View original content to download multimedia: SOURCE Evolent Health, Inc.
Yahoo
03-07-2025
- Business
- Yahoo
JMP Maintains Price Target and Market Outperform Rating on Evolent Health (EVH)
Evolent Health, Inc. (NYSE:EVH) is one of the top 10 healthcare AI stocks to buy according to hedge funds. JMP Securities reaffirmed its Market Outperform rating and $13.00 price target on Evolent Health, Inc. (NYSE:EVH), highlighting a more stable and promising outlook for the company. The firm described Evolent's current risk/reward profile as 'favorably skewed,' citing a series of operational improvements and strategic shifts that have put the company on firmer footing than in recent years. A doctor looking at their computer, discussing their patient's care options with a group of experts. Evolent, which provides value-based care solutions to payers and providers, has made notable progress in restructuring its risk-based arrangements and enhancing contracting mechanisms. These efforts have contributed to a healthier balance of performance obligations and upside potential. JMP noted that a strong pipeline of new business and improved visibility into existing partnerships support the firm's bullish view. While 2025 is expected to be a trough earnings year, JMP expressed increased confidence in Evolent's profit trajectory going forward. A key factor is the anticipated moderation in oncology-related cost trends, which have historically posed volatility in the company's earnings profile. Evolent Health, Inc. (NYSE:EVH) operates as a healthcare AI company, using predictive analytics and machine learning to manage complex populations, optimize clinical interventions, and reduce unnecessary costs. Its platform supports providers in making data-informed decisions, particularly in specialties like oncology and cardiology. With improved structural alignment and growing technological leverage, Evolent is well-positioned to capture long-term value in the transition to outcome-driven healthcare. While we acknowledge the potential of EVH to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than EVH and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Best Biotech Stocks To Invest In Now and 12 Best Healthcare Stocks to Buy Now. Disclosure: None.
Yahoo
20-06-2025
- Business
- Yahoo
Evolent reiterates Q2 and full year guidance for Adjusted EBITDA
Notes accelerating 2026 revenue bookings forecast Secures incremental non-dilutive financing WASHINGTON, June 20, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced that based on leading indicators and paid claims data through May, it continues to experience oncology cost trend below expectations coming into 2025. Evolent is reiterating its Q2 2025 Adjusted EBITDA guidance of $33M-$40M and its full year Adjusted EBITDA guidance of $135M-165M. John Johnson, Evolent's Chief Financial Officer, noted, "We are pleased to see oncology trend remaining below forecast now for the first two thirds of the quarter. We remain confident in meeting or beating the expectations we set for the 2nd quarter and full year. If these trends continue through June, we would anticipate being in the top half of our range for Q2 Adjusted EBITDA." The company also announced it signed a Commitment Letter with Ares Management Credit funds, securing the option to borrow additional non-dilutive capital, if needed, to address its 2025 Convertible Notes while leaving incremental working capital on its balance sheet to support Evolent's accelerating organic growth pipeline. Seth Blackley, Evolent's Chief Executive Officer, noted, "A recent acceleration in our business development activities has led us to significantly increase our forecast for new revenue bookings going into 2026. This option for incremental, non-dilutive capital availability ensures we can execute on any working capital needs associated with that higher growth forecast." About Evolent Evolent (NYSE: EVH) specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable. Evolent serves a national base of leading payers and providers and is consistently recognized as a top place to work in health care nationally. Learn more about how Evolent is changing the way health care is delivered by visiting Contacts:investorrelations@ Forward-Looking Statements Certain statements made in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). A forward-looking statement is a statement that is not a historical fact and, without limitation, includes any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like: "believe," "anticipate," "expect," "estimate," "aim," "predict," "potential," "continue," "plan," "project," "will," "should," "shall," "may," "might" and other words or phrases with similar meaning in connection with a discussion of future operating or financial performance. In particular, these include statements relating to the company's full year and second quarter 2025 guidance, availability of borrowings under the commitment letter, sufficiency of capital for the company's working capital needs associated with a higher growth forecast, and the company's forecast for new revenue bookings going into 2026. The company intends such forward-looking statements to be covered under the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. By their nature, forward-looking statements are subject to numerous factors, risks and uncertainties that could cause actual outcomes and results to be materially different from those projected. These risks and uncertainties are discussed under the headings "Forward-Looking Statements - Cautionary Language," and "Risk Factors," in the company's Annual Report on Form 10-K for the year ended December 31, 2024, which is on file with the U.S. Securities and Exchange Commission (the "SEC"), and in the company's other filings with the SEC, including its Quarterly Report on Form 10-Q for the period ended March 31, 2025, filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statements were made. Except for any ongoing obligation to disclose material information as required by the United States federal securities laws, the company does not have any intention or obligation to publicly update or revise any forward-looking statements after issuing this release, whether to reflect any future events or circumstances or otherwise Non-GAAP Measures The company does not believe it can meaningfully reconcile guidance for non-GAAP Adjusted EBITDA to net income (loss) attributable to common shareholders of Evolent Health, Inc. because the company cannot provide guidance for the more significant reconciling items between net income (loss) attributable to common shareholders of Evolent Health, Inc. and Adjusted EBITDA without unreasonable effort. This is due to the fact that future period non-GAAP guidance includes adjustments for items not indicative of our core operations, and as a result from changes to our business due to transactions and other events. Such items may, from time to time, include loss on repayment/extinguishment of debt; gain (loss) from equity method investees, loss on option exercise, change in fair value of contingent consideration, change in tax receivable agreement liability, other income (expense), gain (loss) on disposal of non-strategic assets, right-of-use asset impairments, losses on lease terminations, repositioning costs, stock-based compensation expense, severance costs, dividends and accretion on Series A Preferred Stock and transaction-related costs. Such adjustments may be affected by changes in ongoing assumptions, judgements, as well as nonrecurring, unusual or unanticipated charges, expenses or gains (losses) or other items that may not directly correlate to the underlying performance of our business operations. The exact amount of these adjustments is not currently determinable but may be significant. View original content to download multimedia: SOURCE Evolent Health, Inc.
Yahoo
10-06-2025
- Business
- Yahoo
EVH Q1 Earnings Call: Oncology Navigation Launch and AI Automation Drive Strategic Focus
Healthcare solutions company Evolent Health (NYSE:EVH) reported Q1 CY2025 results exceeding the market's revenue expectations , but sales fell by 24.4% year on year to $483.6 million. Revenue guidance for the full year exceeded analysts' estimates, but next quarter's guidance of $455 million was less impressive, coming in 9.4% below expectations. Its non-GAAP profit of $0.06 per share was 33% below analysts' consensus estimates. Is now the time to buy EVH? Find out in our full research report (it's free). Revenue: $483.6 million vs analyst estimates of $461.2 million (24.4% year-on-year decline, 4.9% beat) Adjusted EPS: $0.06 vs analyst expectations of $0.10 (33% miss) Adjusted EBITDA: $36.86 million vs analyst estimates of $33.82 million (7.6% margin, 9% beat) The company reconfirmed its revenue guidance for the full year of $2.09 billion at the midpoint EBITDA guidance for the full year is $150 million at the midpoint, in line with analyst expectations Operating Margin: -0.3%, up from -2.1% in the same quarter last year Sales Volumes rose 6.6% year on year (19.5% in the same quarter last year) Market Capitalization: $982.5 million Evolent Health's first quarter performance was shaped by evolving customer demand for specialty condition management and continued expansion within its core product areas. CEO Seth Blackley highlighted the company's addition of five new revenue agreements across oncology, musculoskeletal, and surgical management lines, attributing these wins to Evolent Health's ability to address complex clinical needs for both new and existing clients. The company also completed contractual transitions impacting its revenue mix, most notably shifting certain Performance Suite contracts from gross to net accounting, while maintaining strong renewal rates with major health plan partners. Management called out initial traction for its AuthIntel AI automation solution, noting early improvements in clinician satisfaction and process efficiency. Despite these operational gains, leadership acknowledged the quarter's underlying margin improvement was not fully realized in reported figures, as claims trends and contract transitions continued to influence financial results. Looking forward, management emphasized a focus on scaling its new oncology navigation platform and further integrating automation to drive both growth and profitability. Seth Blackley stated, 'Our oncology navigation solution combines internally developed protocols, digital tools, and newly acquired navigation assets to deliver a more comprehensive care management experience.' The company expects these innovations to expand its addressable market and enhance value delivered to health plan clients, particularly as payers seek solutions to manage rising specialty care costs. CFO John Johnson noted that Evolent Health is closely monitoring medical cost trends, particularly in oncology, but will not update its guidance until additional claims data provides a clearer trend. The leadership team also highlighted ongoing efforts to optimize contract structures and automate claim reviews, aiming to accelerate operational efficiencies and improve member outcomes in the coming quarters. Management attributed the quarter's outcomes to contract transitions, new business wins in specialty management, and the initial rollout of AI-driven automation, while also launching a major oncology navigation platform. Contract transitions impacted revenue: The shift of certain Performance Suite contracts from gross to net accounting influenced reported revenue, with CFO John Johnson explaining these changes were anticipated and EBITDA-neutral, but temporarily inflated topline results. Specialty management platform growth: Five new agreements were signed, including first-time contracts for surgical management with national and regional health plans, and geographic expansion of oncology and musculoskeletal solutions with existing clients, resulting in approximately 1 million additional covered lives. Oncology navigation launch: Evolent Health officially launched its integrated oncology navigation solution, combining in-house protocols, newly acquired navigation assets from Oncology Care Partners, and the Careology digital app. Management reported early client deployments and indicated this offering could increase savings opportunities by 10-20% compared to prior solutions. AI and automation adoption: The company deployed its AuthIntel AI tool to streamline clinical review processes, delivering faster patient resolutions and improved clinician satisfaction. While still early, management sees significant long-term opportunity for automation to boost productivity and reduce manual workload. Performance Suite margin maturation: Margin improvement initiatives are underway, with management noting favorable leading indicators in oncology cost trends, though full benefit realization awaits more complete claims data. John Johnson emphasized that annual contract repricing and corridor structures are helping maintain margin stability across evolving payer mixes. Evolent Health's outlook is driven by scaling its oncology navigation solution, increasing automation, and maintaining disciplined contract management to navigate evolving policy and industry trends. Oncology navigation platform scaling: Management expects broader adoption of the integrated oncology navigation solution to increase the value delivered to clients, citing early evidence of improved patient engagement and potential for expanded savings, especially as the offering addresses both clinical and non-clinical aspects of cancer care. AI-driven productivity gains: Leadership anticipates that further automation of claims reviews and clinical workflows will reduce processing times and operational costs through 2025 and beyond, while reiterating that AI is used only to support approvals and not to restrict access to care. Policy and payer dynamics: The company is monitoring potential policy changes in Medicare and Medicaid but expects limited near-term impact due to contract structures allowing for rate adjustments if drug costs rise. Diversification across payer types and continued annual repricing cycles are expected to help buffer against macro and regulatory headwinds. In the coming quarters, the StockStory team will watch (1) the pace and client uptake of the new oncology navigation platform, (2) evidence of sustained margin improvement from expanding automation and contract repricing, and (3) any shifts in medical cost trends—particularly in oncology and cardiology—that could influence guidance updates. Additional focus will be on the company's execution of planned Performance Suite go-lives and integration of newly acquired assets. Evolent Health currently trades at a forward P/E ratio of 15.3×. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it's free). The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27-05-2025
- Business
- Yahoo
Evolent Health, Amphastar Pharmaceuticals, Iridium, and Magnite Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +2.0%, S&P 500 +2.0%) as President Trump postponed the planned 50% tariff on European Union imports, shifting the start date to July 9, 2025. Companies with substantial business ties to Europe likely had some relief as the delay reduced near-term cost pressures and preserved cross-border demand. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Healthcare Technology for Providers company Evolent Health (NYSE:EVH) jumped 5.6%. Is now the time to buy Evolent Health? Access our full analysis report here, it's free. Generic Pharmaceuticals company Amphastar Pharmaceuticals (NASDAQ:AMPH) jumped 5%. Is now the time to buy Amphastar Pharmaceuticals? Access our full analysis report here, it's free. Satellite Telecommunication Services company Iridium (NASDAQ:IRDM) jumped 5.7%. Is now the time to buy Iridium? Access our full analysis report here, it's free. Advertising & Marketing Services company Magnite (NASDAQ:MGNI) jumped 5.6%. Is now the time to buy Magnite? Access our full analysis report here, it's free. Iridium's shares are quite volatile and have had 17 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. Iridium is down 11.2% since the beginning of the year, and at $26.27 per share, it is trading 21.7% below its 52-week high of $33.57 from October 2024. Investors who bought $1,000 worth of Iridium's shares 5 years ago would now be looking at an investment worth $1,099. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Sign in to access your portfolio
